Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP568423.RA0wStgKAII-fd6s26Wgiugl_wvsqXcvzkQz1glo6HEsU130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP568423.RA0wStgKAII-fd6s26Wgiugl_wvsqXcvzkQz1glo6HEsU130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP568423.RA0wStgKAII-fd6s26Wgiugl_wvsqXcvzkQz1glo6HEsU130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP568423.RA0wStgKAII-fd6s26Wgiugl_wvsqXcvzkQz1glo6HEsU130_provenance.
- NP568423.RA0wStgKAII-fd6s26Wgiugl_wvsqXcvzkQz1glo6HEsU130_assertion description "[Chronic exposure to high levels of 5-HT (from metastatic carcinoid tumours), the anorectic drug fenfluramine and its metabolites, as well as the ecstasy drug 3,4-methylenedioxymethamphetamine (MDMA) and its metabolite 3,4-methylenedioxyamphetamine (MDA) are associated with proliferative disease and thickening of cardiac valves, mediated through 5-HT2B receptors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP568423.RA0wStgKAII-fd6s26Wgiugl_wvsqXcvzkQz1glo6HEsU130_provenance.
- NP568423.RA0wStgKAII-fd6s26Wgiugl_wvsqXcvzkQz1glo6HEsU130_assertion evidence source_evidence_literature NP568423.RA0wStgKAII-fd6s26Wgiugl_wvsqXcvzkQz1glo6HEsU130_provenance.
- NP568423.RA0wStgKAII-fd6s26Wgiugl_wvsqXcvzkQz1glo6HEsU130_assertion SIO_000772 16960982 NP568423.RA0wStgKAII-fd6s26Wgiugl_wvsqXcvzkQz1glo6HEsU130_provenance.
- NP568423.RA0wStgKAII-fd6s26Wgiugl_wvsqXcvzkQz1glo6HEsU130_assertion wasDerivedFrom befree-2016 NP568423.RA0wStgKAII-fd6s26Wgiugl_wvsqXcvzkQz1glo6HEsU130_provenance.
- NP568423.RA0wStgKAII-fd6s26Wgiugl_wvsqXcvzkQz1glo6HEsU130_assertion wasGeneratedBy ECO_0000203 NP568423.RA0wStgKAII-fd6s26Wgiugl_wvsqXcvzkQz1glo6HEsU130_provenance.
- befree-2016 importedOn "2016-02-19" NP568423.RA0wStgKAII-fd6s26Wgiugl_wvsqXcvzkQz1glo6HEsU130_provenance.